Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Fibrosis Interstitial Clear all
Completed No phase listed Observational

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT01417520
View directory record Official record
Conditions
Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 28, 2026, 3:48 PM EDT
Recruiting Phase 2 Interventional

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05571059
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ifetroban Sodium, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

NCT03573505
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 28, 2026, 3:48 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis

NCT02151435
View directory record Official record
Conditions
IPF
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 28, 2026, 3:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Completed No phase listed Observational

Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis

NCT01107028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard pulmonary rehabilitation program
Other
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 28, 2026, 3:48 PM EDT
Completed No phase listed Observational

Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT01071707
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

NCT00000990
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
33
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 3:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06317285
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GSK3915393, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Newport Beach, California • Jacksonville, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional

SD, IL-13 Production Rate in IPF

NCT00532233
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01890265
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 3 Interventional Results available

The Effect of N115 on Coughing in IPF Patients

NCT06037408
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hialeah Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 28, 2026, 3:48 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Advancing Prevention of Pulmonary Fibrosis

NCT04564183
View directory record Official record
Conditions
IPF, Pulmonary Fibrosis, ILD
Interventions
Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test
Other · Radiation · Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT00786201
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 28, 2026, 3:48 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 2 Interventional Results available

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

NCT00903331
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ACT-064992 (macitentan), Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 28, 2026, 3:48 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Palm Spring, California • Redding, California • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 1 Interventional

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

NCT02510937
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
CC-90001
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Michigan City, Indiana • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 28, 2026, 3:48 PM EDT
Completed No phase listed Observational

Segmental Bronchoalveolar Lavage

NCT00001618
View directory record Official record
Conditions
Asthma, Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 28, 2026, 3:48 PM EDT
Recruiting Phase 1 Interventional

Nucleoside Therapy in Patients With Telomere Biology Disorders

NCT06817590
View directory record Official record
Conditions
Telomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson Syndrome, Telomere Biology Disorders With Bone Marrow Failure, Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Pulmonary Fibrosis, Familial (Telomere Biology Disorder)
Interventions
deoxycytidine, deoxythymidine
Drug
Lead sponsor
Suneet Agarwal
Other
Eligibility
1 Year to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 3:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

NCT05684289
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 28, 2026, 3:48 PM EDT